Alan Bash
Chief Executive Officer at Zielbio, Inc.
Alan Bash active positions
| Companies | Position | Start | End |
|---|---|---|---|
Zielbio, Inc.
 Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA. | Director/Board Member | 2023-01-02 | - |
| Chief Executive Officer | 2023-01-02 | - |
Career history of Alan Bash
Former positions of Alan Bash
| Companies | Position | Start | End |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
| CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 2022-02-28 | 2022-05-30 |
| Chief Executive Officer | 2022-02-28 | - | |
| President | 2022-02-28 | - |
Training of Alan Bash
| Georgetown University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Statistics
International
| United States | 6 |
Operational
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| President | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 2 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Zielbio, Inc.
Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA. | Health Technology |
- Stock Market
- Insiders
- Alan Bash
- Experience
